共 39 条
[1]
Zhanel GG(2019)Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli Drugs 79 271-289
[2]
Golden AR(2018)In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria Antimicrob Agents Chemother 21 226-240
[3]
Zelenistky S(2021)Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomized, open-label, multicenter, pathogen-focused, descriptive, phase 3 trial Lancet Infect Dis 18 1319-1328
[4]
Ito A(2018)Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomized, double-blind, non-inferiority trial Lancet Infect Dis 21 213-225
[5]
Sato T(2021)Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomized, double-blind, phase 3, non-inferiority trial Lancet Infect Dis 3 dlab174-e2221
[6]
Ota M(2021)Cefiderocol treatment for carbapenem-resistant JAC Antimicrob Resist 10 652-2024
[7]
Bassetti M(2020) infection in ICU during COVID-19 pandemic: a multicentre cohort study OFID 66 e02142-undefined
[8]
Echols R(2021)Cefiderocol for extensively drug-resistant gram-negative bacterial infections: real-world experience from a case series and review of the literature Antibiotics (Basel) 72 2021-undefined
[9]
Matsunaga Y(2022)Cefiderocol-based combination therapy for “difficult-to-treat” gram-negative severe infections: real-life case series and future perspectives Antimicrob Agents Chemother 4 366-undefined
[10]
Portsmouth S(2021)Cefiderocol-compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Clin Infect Dis 3 dlab188-undefined